Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

An antimicrobial peptide of the cathelicidin family that provides innate immune defense by killing pathogens and modulating inflammation and wound healing.

Quick Stats
Studies 2230
Trials 95
Formula C205H340N60O53
Clear All
Utility 2
pubmed Dec 1, 2009

Fluorescence and UV resonance Raman study of peptide-vesicle interactions of human cathelicidin LL-37 and its F6W and F17W mutants.

Gable. Jonathan E JE; Schlamadinger. Diana E DE; Cogen. Anna L AL; Gallo. Richard L RL; Kim. Judy E...

This study shows that two engineered versions of the human antimicrobial peptide LL‑37 work just as well as the natural peptide at killing bacteria and breaking cell membranes. Using special light‑based techniques, the researchers found that the tryptophan tags they added behave similarly in water, carbonate solutions, and when the peptide interacts with lipid membranes, supporting a membrane‑disruption mode of action.

Utility 2
pubmed Jan 22, 2010

The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium.

Barlow. Peter G PG; Beaumont. Paula E PE; Cosseau. Celine C; Mackellar. Annie A; Wilkinson. Thomas S...

The study shows that the natural protein LL‑37, which our bodies make in the lungs, helps kill airway cells that are infected with the bacteria Pseudomonas aeruginosa. It does this by triggering a controlled cell‑death process (apoptosis) only when both the peptide and live bacteria are present, using the cell’s mitochondria and caspase enzymes. High, non‑physiological levels of LL‑37 cause a different, uncontrolled cell death.

Utility 2
pubmed Feb 28, 2011

Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37.

Jiang. Ziqing Z; Higgins. Michael P MP; Whitehurst. James J; Kisich. Kevin O KO; Voskuil. Martin I M...

Researchers tested specially designed short proteins (peptides) against regular and drug‑resistant TB bacteria. The D‑form peptide called D5 stopped bacterial growth at low concentrations, and a similar peptide D1 worked almost as well but was less harmful to human cells. The natural human peptide LL‑37 didn’t do much against TB.

Utility 2
pubmed Apr 23, 2010

Review: Defensins and cathelicidins in lung immunity.

Tecle. Tesfaldet T; Tripathi. Shweta S; Hartshorn. Kevan L KL

Defensins and the peptide LL‑37 are natural proteins made by immune cells and airway lining cells that kill germs and help control inflammation in the lungs. This review explains the different types of defensins, their broad antimicrobial actions, and how they also recruit immune cells and can calm inflammation. It notes that LL‑37 works similarly, but we still need to figure out exactly how much each contributes to lung health.

Utility 2
pubmed Apr 15, 2011

Labisia pumila var. alata reduces bacterial load by inducing uroepithelial cell apoptosis.

Fazliana. Mansor M; Ramos. Nubia L NL; Lüthje. Petra P; Sekikubo. Musa M; Holm. Asa A; Wan Naza...

A Malaysian herb called Labisia pumila var. alata (LPva) can make bladder cells die in a controlled way, which helps lower the number of urinary‑tract bacteria that hide inside those cells. It doesn't kill the bacteria directly and doesn't change levels of the natural antimicrobial peptide LL‑37, but by prompting the infected cells to undergo apoptosis it reduces bacterial invasion.

Utility 2
pubmed Feb 13, 2012

Streptococcus pyogenes infection of tonsil explants is associated with a human β-defensin 1 response from control but not recurrent acute tonsillitis patients.

Bell. S S; Howard. A A; Wilson. J A JA; Abbot. E L EL; Smith. W D WD; Townes. C L CL; Hirst. B H BH;...

The study looked at how the natural antimicrobial peptides LL‑37 (hCAP‑18) and beta‑defensins behave in tonsils during a strep throat infection. It found that, when the infection is active, the tonsil cells make less LL‑37 and defensins, especially in people who get frequent tonsillitis, suggesting these peptides help protect the throat but are suppressed during infection.

Utility 2
pubmed Oct 5, 2011

Neutrophil-derived cathelicidin protects from neointimal hyperplasia.

Soehnlein. Oliver O; Wantha. Sarawuth S; Simsekyilmaz. Sakine S; Döring. Yvonne Y; Megens. Remc...

Researchers found that the natural peptide LL‑37, which is released by neutrophils, helps blood vessels heal faster after a stent is placed, cutting down the thickening that can block the artery again. In mice, a tiny stent coated with LL‑37 reduced this re‑narrowing, showing the peptide’s potential to improve vascular recovery.

Utility 2
pubmed Oct 7, 2009

Antimicrobial activity of human prion protein is mediated by its N-terminal region.

Pasupuleti. Mukesh M; Roupe. Markus M; Rydengård. Victoria V; Surewicz. Krystyna K; Surewicz. W...

Researchers found that the front part of the human prion protein can kill bacteria and fungi, acting much like the well‑known antimicrobial peptide LL‑37 by punching holes in cell membranes. Unlike LL‑37, these prion‑derived pieces don’t form a helix when they hit bacterial membranes, and the protein’s levels go up when skin is wounded, hinting it helps protect wounds.

Utility 2
pubmed 2011

The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells.

Mader. Jamie S JS; Ewen. Catherine C; Hancock. Robert E W RE; Bleackley. Robert C RC

The human antimicrobial peptide LL-37 can kill regulatory T cells (the immune cells that calm down immune responses) at much lower doses than it harms other immune cells. It does this by triggering apoptosis through enzymes called granzymes, and the effect can be both caspase‑dependent and independent. This suggests LL-37 might be used to dampen the suppressive immune environment around tumors.

Utility 2
pubmed Sep 1, 2010

Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.

Pence. Morgan A MA; Rooijakkers. Suzan H M SH; Cogen. Anna L AL; Cole. Jason N JN; Hollands. Andrew...

The study shows that a protein made by dangerous strep bacteria (SIC) can grab and neutralize the human antimicrobial peptide LL‑37, helping the bacteria survive in blood and cause infection. This means LL‑37’s natural defense role can be blocked by certain bacterial strains.

Utility 2
pubmed Aug 12, 2011

Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early endothelial progenitor cells reveals highly differential gene expression.

Ahrens. Ingo I; Domeij. Helena H; Topcic. Denijal D; Haviv. Izhak I; Merivirta. Ruusu-Maaria RM; Agr...

Scientists figured out a way to grow a lot more early endothelial progenitor cells (EPCs) from umbilical cord blood in the lab. During this process the gene for the peptide LL‑37 (CAMP) became the most strongly increased, along with other genes linked to heart protection and new blood‑vessel growth.

Utility 2
pubmed Oct 21, 2009

Apurinic/apyrimidinic endonuclease 1 is a key modulator of keratinocyte inflammatory responses.

Lee. Hye-Mi HM; Yuk. Jae-Min JM; Shin. Dong-Min DM; Yang. Chul-Su CS; Kim. Kwang-Kyu KK; Choi. Dae-K...

The study shows that a protein called APE1 controls inflammation in skin cells and also boosts the production of the antimicrobial peptide LL‑37. In psoriasis, APE1 levels are higher, and it helps activate key inflammation pathways. While this reveals a new link, it doesn’t give a clear way to use LL‑37 or APE1 in everyday health hacks yet.

Utility 2
pubmed 2010

Recent patents on antimicrobial peptides.

Pathan. Firoz K FK; Venkata. Deepa A DA; Panguluri. Siva K SK

This paper reviews recent patents on antimicrobial peptides, highlighting that scientists are trying to turn these natural antibiotics into new medicines. It mentions that the human peptide LL‑37 and its modified versions are being patented for helping wounds heal, but it doesn’t give any dosing or how‑to‑use details. The focus is on the patent landscape rather than new experimental results you could try right now.

Utility 2
pubmed 2010

What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies.

Rupec. Rudolf A RA; Boneberger. Susanne S; Ruzicka. Thomas T

The abstract says that eczema (atopic dermatitis) is linked to genetics, skin barrier problems, and a messed‑up immune response, and that the skin’s natural antimicrobial peptide LL‑37 is lower in affected people. It doesn’t give a new treatment, just points out that LL‑37 and other defenses are part of the disease puzzle.

Utility 2
pubmed Oct 2, 2009

A comparative study on the interactions of SMAP-29 with lipid monolayers.

Neville. Frances F; Ivankin. Andrey A; Konovalov. Oleg O; Gidalevitz. David D

The study shows that the human peptide LL‑37 and the animal peptide SMAP‑29 both target negatively charged cell membranes, but SMAP‑29 needs a lot more molecules to break the membrane even though it’s more positively charged. This means that a peptide’s shape and size matter as much as its charge when it interacts with membranes.

Utility 2
pubmed Oct 30, 2009

Expression and regulation of antimicrobial peptide rCRAMP after bacterial infection in primary rat meningeal cells.

Brandenburg. Lars-Ove LO; Varoga. Deike D; Nicolaeva. Nicoletta N; Leib. Stephen L SL; Podschun. Rai...

The study shows that brain‑covering cells in rats make the antimicrobial peptide LL‑37’s counterpart (rCRAMP) when they sense bacterial signals, and this peptide can kill bacteria in lab tests. It also shows that inflammation signals boost its production, and that the peptide shows up in infected rat brains. However, the work is basic science in rats and doesn’t give dosage or safety info for humans.

Utility 2
pubmed Feb 28, 2010

Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules.

Metz-Boutigue. Marie-Hélène MH; Shooshtarizadeh. Peiman P; Prevost. Gilles G; Haikel. Yous...

This paper reviews how natural antimicrobial peptides like LL‑37 act as the body’s first line of defense in skin and gut, killing microbes and shaping immune responses. It notes that LL‑37 levels rise in psoriasis but drop in eczema, linking these peptides to inflammation and disease states, but it doesn’t give any dosing or treatment tips.

Utility 2
pubmed May 31, 2010

Recognition of nucleic acids by Toll-like receptors and development of immunomodulatory drugs.

Kuznik. A A; Panter. G G; Jerala. R R

The paper explains how certain immune sensors (TLR3,7,8,9) spot DNA and RNA inside cells, and how the natural peptide LL‑37 can bind these nucleic acids and help trigger those sensors. While this shows LL‑37’s role in immune activation, it doesn’t give any direct dosing tips or protocols for everyday use.

Utility 2
pubmed Sep 22, 2010

Permeabilization of fungal hyphae by the plant defensin NaD1 occurs through a cell wall-dependent process.

van der Weerden. Nicole L NL; Hancock. Robert E W RE; Anderson. Marilyn A MA

This study looked at how a plant protein called NaD1 kills fungus and compared it to other antimicrobial peptides, including the human peptide LL‑37. It found that NaD1 needs the fungus’s cell wall to work, while LL‑37 is thought to act mainly by breaking cell membranes, but the paper didn’t reveal any new tricks for using LL‑37 in humans.